Write in a clean editor, then format for Journal of Central Nervous System Disease in one click — DocuGuru applies the official SAGE template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Journal of Central Nervous System Disease is a peer-reviewed journal published by SAGE, covering Multiple Sclerosis Research Studies, Acute Ischemic Stroke Management, Peripheral Neuropathies and Disorders.
| Publisher | SAGE |
|---|---|
| Reference style | Author–year (Harvard) Author–year — (Smith, 2023) in the text Smith, A., Jones, B. and Lee, C. (2023) 'A representative article title', Journal of Central Nervous System Disease, 12(3), pp. 45–58.
Formats any DOI in Journal of Central Nervous System Disease style. No sign-up. |
| Publishes research in | Multiple Sclerosis Research Studies Acute Ischemic Stroke Management Peripheral Neuropathies and Disorders Stroke Rehabilitation and Recovery Epilepsy research and treatment |
| ISSN | 1179-5735 |
| Citation impact (2-yr) | 2.49 |
| h-index | 33 |
| i10-index | 122 |
| Total citations | 5,611 |
| Article processing charge | $1,500 |
| Open access | Yes |
| Top institutions publishing here | The University of Texas Southwestern Medical Center |
| Journal website | journals.sagepub.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Disease-modifying treatment strategies for Alzheimer disease (AD) are still under extensive research. Nowadays, only symptomatic treatments exist for this disease, all trying to counterbalance the neurotransmitter disturbance: 3 cholinesterase inhibitors and memantine. To block the progression of the disease, therapeutic agents are supposed to interfere with the pathogenic steps responsible for the clinical symptoms, classically…
Tumor necrosis factor α (TNF-α) plays a central role in the pathophysiology of Alzheimer's disease (AD). Food and Drug Administration-approved biologic TNF-α inhibitors are thus a potential treatment for AD, but they do not cross the blood-brain barrier. In this short review, we discuss the involvement of TNF-α in AD, challenges associated with the development…
Alzheimer's disease (AD) is a chronic disabling disease that affects the central nervous system. The main consequences of AD include the decline of cognitive functions and language disorders. One of the causes leading to AD is the decrease of neurotransmitter acetylcholine (ACh) levels in the brain, in part due to a higher activity of acetylcholinesterase…
Obsessive-compulsive disorder (OCD) is a neuropsychiatric illness that often develops in childhood, affects 1%-2% of the population, and causes significant impairment across the lifespan. The first step in identifying and treating OCD is a thorough evidence-based assessment. This paper reviews the administration pragmatics, psychometric properties, and limitations of commonly used assessment measures for adults and…
Sepsis is a systemic inflammatory disease resulting from an infection. This disorder affects 750 000 people annually in the United States and has a 62% rehospitalization rate. Septic symptoms range from typical flu-like symptoms (eg, headache, fever) to a multifactorial syndrome known as sepsis-associated encephalopathy (SAE). Patients with SAE exhibit an acute altered mental status…
